The tree · Window · Happens to the world · Could be decided within 1 to 5 years
A drug regulator accepts a biological measure of aging as a trial's primary endpoint
Trials of aging drugs today have to wait for disease or death, which takes decades and is why nobody runs them. A regulator accepting a biological measure of aging (an epigenetic clock, say, a blood test that reads how old a person's cells behave) as the primary endpoint of a pivotal trial would shorten those trials from decades to years. It is a separate rung between the 2015 composite-endpoint precedent and an approvable indication, and it is what would make a first approved aging drug arrive inside a working lifetime rather than after one.
The test: what counts as it having happened
The US Food and Drug Administration or the European Medicines Agency accepts, in published guidance, a qualified-biomarker decision, or the published design of a pivotal trial it has agreed to, a biological measure of aging (an epigenetic, proteomic, or equivalent molecular clock) as the primary endpoint on which a drug may be approved, in place of a clinical outcome such as disease onset or death.
Settled by: The regulator's published guidance, biomarker qualification record, or the agreed trial design on the public registry
The odds, by how long I live
| baselineto 2071 ± 8 | moderateto 2080 | strongto 2095 | radicalto 2136 | openno deadline |
|---|---|---|---|---|
| 55% | 60% | 70% | 85% | 90% |
Each column is a different guess at how long I live, from current trends (baseline) to open-ended. The number is the chance this happens before that deadline, assuming everything it depends on happens first. As of September 20th, 2026.
Why these numbers: Biomarker qualification programs exist and aging clocks are improving fast, but no clock is yet validated as a surrogate for outcomes and regulators are slow to accept surrogates that have not predicted a hard endpoint in a trial; priced at the indication node's level because the two rungs rise and fall together. Proposed by Claude September 20th, 2026 with the node's addition, I accepted.
What this one is worth
Nothing. The headline number does not rest on this step at any remove, so however it turns out, the chance that I live and work off Earth does not change. That is not a judgement that it does not matter. It is what the tree says: this step feeds a tier above the one the headline asks about, or sits beside the equation rather than in it.
The last 3 checks
Once a week the tree is read against the news, node by node, against the test above. Open a line to see what that week held. Every check ever made on this node is on the Radar page.
-
2026-11-01 Nothing new
No qualified aging-clock biomarker or regulator-agreed pivotal design was found; commentary says no clock has FDA surrogate status. Registered clock-endpoint trials such as NCT07888595 show no sign of regulator agreement.
-
2026-10-25 Nothing new
No regulator has accepted an epigenetic or proteomic clock as a primary endpoint. Commentary of August 2026 says only eight biomarkers have been qualified through the FDA programme and no aging clock is among them.
-
2026-10-18 Nothing new
No regulator has accepted an aging clock as a primary endpoint; commentary dated August 2026 says no epigenetic clock is among the eight biomarkers FDA has qualified, and trials using clocks are exploratory.
Notes
Added September 20th, 2026 under step 27, item 1 (docs/reviews/2026-09-19-rulings.md, decided September 19th, 2026): raised by Gemini as a missing node; gates W-first-drug-approved-to-slow-aging beside the indication node. The caution from item 31 applies: this is a rung toward approval, not a prerequisite for the death-rate trial or the lifespan record.
Think this estimate is wrong?
Here's how to tell me, and
what happens next.
The record itself is data/W-window.toml in the public repository.